NRIX Surges Ahead
NRIX Surges Ahead
Financially, NRIX’s shares have risen 38.5 % year‑to‑date, outperforming the industry’s 7.4 % growth, and the company has been upgraded to a Zacks Rank #2 (Buy). The upgrade reflects an upward trend in earnings estimates, with analysts steadily raising their forecasts. NRIX is projected to earn –$2.69 per share for the fiscal year ending November 2026, and the company ranks in the top 20 % of Zacks‑covered stocks for estimate revisions, suggesting potential near‑term upside.
11/09/2026 | Nurix Therapeutics, Inc.